chronic

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…

4 weeks ago

PEMF Therapy Emerges as a Leading 2025 Wellness Trend for Drug-Free Pain Relief; Grooni Earthings Pro Collection Meets Rising Demand

SHERIDAN, WY , Aug. 26, 2025 (GLOBE NEWSWIRE) -- As consumers seek science-informed, non-pharmacological options for chronic pain and recovery,…

1 month ago

Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure

Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 /PRNewswire/ -- Berlin…

2 months ago

CCS Presents Four Peer-Reviewed Posters at American Diabetes Associations 85th Scientific Sessions

CCS’s latest evidence-based research reinforces the most innovative and intelligent approaches to improving adherence and outcomes, while reducing the total…

3 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

3 months ago

Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…

4 months ago